Dysfunctional high-density lipoprotein and atherogenesis

Abstract

High-density lipoprotein (HDL) plays a major role in reverse cholesterol transport (RCT) but also exhibits, anti-inflammatory, endothelial/vasodilatory, anti-thrombotic, antioxidant, anti-aggregating, anticoagulant and cytoprotective functions, which enhance its protective effect against cardiovascular disease. However, the function of HDL is dependent upon genetic, environmental and lifestyle factors. Modification of the protein or lipid components of HDL in certain conditions may convert the HDL particles from anti-inflammatory to pro-inflammatory and pro-atherogenic by limiting their ability to promote RCT and to prevent LDL modification. In our review, we will present the clinical and scientific data pertaining to the factors and conditions that impair HDL functionality and we will discuss the effects of dysfunctional HDL on atherogenesis.

Keywords

High-density lipoprotein / high-density lipoprotein functionality / atherogenesis / cardiovascular disease

References

[1] Barter P,LaRosa JC,Szarek M.HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events..N Engl J Med2007;357:1301-10

[2] Jafri H,Karas RH.Meta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk..Ann Intern Med2010;153:800-8

[3] Rye KA.Cardioprotective functions of HDLs..J Lipid Res2014;55:168-79 PMCID:PMC3886656

[4] Barter PJ,Rye KA.Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells..Curr Opin Lipidol2002;13:285-8

[5] Kosmas CE,Sourlas A,Campos FN.High-density lipoprotein (HDL) functionality and its relevance to atherosclerotic cardiovascular disease..Drugs Context2018;7:212525 PMCID:PMC5877920

[6] Favari E,Sorci-Thomas MG.High-density lipoprotein functionality as a new pharmacological target on cardiovascular disease: unifying mechanism that explains high-density lipoprotein protection toward the progression of atherosclerosis..J Cardiovasc Pharmacol2018;71:325-31

[7] Rohatgi A,Berry JD,Ayers CR.HDL cholesterol efflux capacity and incident cardiovascular events..N Engl J Med2014;371:2383-93 PMCID:PMC4308988

[8] Navab M,Van Lenten BJ.HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms..Nat Rev Cardiol2011;8:222-32

[9] Tailleux A.HDL heterogeneity and atherosclerosis..Crit Rev Clin Lab Sci1996;33:163-201

[10] Kosmas CE,Cheng JW,Lerakis S.High-density lipoprotein functionality in coronary artery disease..Am J Med Sci2014;347:504-8

[11] Kontush A,Chapman MJ.Unraveling the complexities of the HDL lipidome..J Lipid Res2013;54:2950-63 PMCID:PMC3793600

[12] Rader DJ.Molecular regulation of HDL metabolism and function: implications for novel therapies..J Clin Invest2006;116:3090-100 PMCID:PMC1679714

[13] Vaisar T,Green PS,Hoofnagle AN.Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL..J Clin Invest2007;117:746-56 PMCID:PMC1804352

[14] Kontush A,Chapman MJ.Unraveling the complexities of the HDL lipidome..J Lipid Res2013;54:2950-63 PMCID:PMC3793600

[15] Tölle M,Schuchardt M,Prüfer N.High-density lipoprotein loses its anti-inflammatory capacity by accumulation of pro-inflammatory-serum amyloid A..Cardiovasc Res2012;94:154-62

[16] Jahangiri A.High-density lipoprotein and the acute phase response..Curr Opin Endocrinol Diabetes Obes2010;17:156-60 PMCID:PMC2917341

[17] Van Lenten BJ,de Beer FC,McIntyre TM.Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures..J Clin Invest1995;96:2758-67 PMCID:PMC185985

[18] Yamamoto K,Sato H,Murakami M.Secreted phospholipase A2, lipoprotein hydrolysis, and atherosclerosis: integration with lipidomics..Anal Bioanal Chem2011;400:1829-42 PMCID:PMC3098357

[19] Kar S,Tripathy RK,Suvarnakar UV.Oxidized phospholipid content destabilizes the structure of reconstituted high density lipoprotein particles and changes their function..Biochim Biophys Acta2012;1821:1200-10

[20] Kameda T,Yano K,Miyazaki A.Effects of myeloperoxidase-induced oxidation on antiatherogenic functions of high-density lipoprotein..J Lipids2015;2015:592594 PMCID:PMC4516847

[21] Chen C.Oxidized low-density lipoprotein contributes to atherogenesis via co-activation of macrophages and mast cells..PLoS One2015;10:e0123088 PMCID:PMC4374860

[22] Otocka-Kmiecik A,Nicholls SJ,Rysz J.Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease?.Prog Lipid Res2012;51:314-24

[23] Navab M,Hough GP,Reddy ST.A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids..J Lipid Res2001;42:1308-17

[24] Salazar J,Ramos E,Rojas J.Dysfunctional high-density lipoprotein: an innovative target for proteomics and lipidomics..Cholesterol2015;2015:296417 PMCID:PMC4655037

[25] Chait A,Oram JF.Thematic review series: the immune system and atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease?.J Lipid Res2005;46:389-403

[26] Nobécourt E,Hansel B,Grimaldi A.Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia..Diabetologia2005;48:529-38

[27] Hedrick CC,Fu MX,Yoo J.Glycation impairs high-density lipoprotein function..Diabetologia2000;43:312-20

[28] Hoang A,Coughlan MT,Forbes JM.Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic properties..Diabetologia2007;50:1770-9

[29] Nobécourt E,Lambert G,Bao S.Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I..Arterioscler Thromb Vasc Biol2010;30:766-72 PMCID:PMC3038672

[30] He BM,Peng ZY.Effects of cigarette smoking on HDL quantity and function: implications for atherosclerosis..J Cell Biochem2013;114:2431-6

[31] McMorrow AM,Connaughton RM,O’Shea D.Obesity and dietary fat modulate HDL function in adolescents: results from a cross-sectional analysis and a randomized, placebo-controlled, crossover trial..FASEB J2016;30:130

[32] Nicholls SJ,Harmer JA,Griffiths KA.Consumption of saturated fat impairs the anti-inflammatory properties of high-density lipoproteins and endothelial function..J Am Coll Cardiol2006;48:715-20

[33] van der Steeg WA,Boekholdt SM,Lindahl C.High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies..J Am Coll Cardiol2008;51:634-42

[34] Qi Y,Liu J,Wang M.Cholesterol-overloaded HDL particles are independently associated with progression of carotid atherosclerosis in a cardiovascular disease-free population: a community-based cohort study..J Am Coll Cardiol2015;65:355-63

[35] Madsen CM,Nordestgaard BG.Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies..Eur Heart J2017;38:2478-86

[36] Hirata A,Watanabe M,Iso H.Association of extremely high levels of high-density lipoprotein cholesterol with cardiovascular mortality in a pooled analysis of 9 cohort studies including 43,407 individuals: the EPOCH-JAPAN study..J Clin Lipidol2018;12:674-84

[37] Khera AV,de la Llera-Moya M,Burke MF.Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis..N Engl J Med2011;364:127-35 PMCID:PMC3030449

[38] Ogura M,Harada-Shiba M.Association between cholesterol efflux capacity and atherosclerotic cardiovascular disease in patients with familial hypercholesterolemia..Arterioscler Thromb Vasc Biol2016;36:181-8

[39] Huang Y,Levison BS,Li L.An abundant dysfunctional apolipoprotein A1 in human atheroma..Nat Med2014;20:193-203 PMCID:PMC3923163

[40] Carnuta MG,Toma L,Niculescu LS.Dysfunctional high-density lipoproteins have distinct composition, diminished anti-inflammatory potential and discriminate acute coronary syndrome from stable coronary artery disease patients..Sci Rep2017;7:7295 PMCID:PMC5544737

[41] Kratzer A,Landmesser U.High-density lipoproteins as modulators of endothelial cell functions: alterations in patients with coronary artery disease..Cardiovasc Res2014;103:350-61

[42] Besler C,Rohrer L,Riwanto M.Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease..J Clin Invest2011;121:2693-708 PMCID:PMC3223817

[43] Angeloni E,Landmesser U,Melina G.Lack of protective role of HDL-C in patients with coronary artery disease undergoing elective coronary artery bypass grafting..Eur Heart J2013;34:3557-62

[44] Briel M,You JJ,Akl EA.Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis..BMJ2009;338:b92 PMCID:PMC2645847